Chemotherapy for early stage endometrial cancer? Should we be using it?

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 1, 2008, Pages 1-3

  Rodriguez, Anne O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM;

ADJUVANT THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; EDITORIAL; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MORBIDITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT;

EID: 38149108390     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f3d9e8     Document Type: Editorial

References (15)

1. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecologic Oncology 2007; 105:7-12.
2. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005; 63:834-838.
3. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744-751.
4. Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiation Oncology Biol Phys 2005; 62:111-117.
5. Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 36:166-171.
6. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent, or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007; 18:409-420.
7. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006; 24:36-44.
8. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006; 95:266-271.
9. Sagae S, Udagawa Y, Susumu N, et al. A randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate risk endometrial carcinoma: a Japan Gynecological Oncology Group study [abstract]. EJC Suppl 2005; 3:265.
10. Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006; 103:155-159.
11. Kodama J, Seki N, Hiramatsu Y. Chemotherapy for high-risk earlystage endometrial cancer. Curr Opin Obstet Gynecol 2007; 19:42-47.
12. Hirai M, Hirono M, Oosaki T, et al. Adjuvant chemotherapy in stage I uterine endometrial carcinoma. Int J Gynecol Obstet 2002; 78:37-44.
13. Aoki Y, Watanabe M, Amikura T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol 2004; 94:333-339.
14. Kodama J, Seki N, Ojima Y, et al. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol 2007; 131:76-80.
15. Ferguson SE, Olshen AB, Viale A, et al. Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clinical Cancer Res 2005; 11:2252-2257.